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c Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy 
d Ospedale M. G. Vannini, Rome, Italy   





Low grade chronic inflammation 
Free light chains 
A B S T R A C T   
CH50 is a screening assay for the activation of the classical complement pathway, the immunoglobulins- 
mediated one, activated in several inflammatory diseases. Adult growth hormone deficiency (aGHD) is recog-
nized as a chronic inflammatory condition, although poorly evaluated under the profile of inflammatory bio-
markers. The aim of this case-control observational study is to analyze CH50 and immunoglobulins G (IgG) 
subclasses production in aGHD, comparing this condition to healthy controls. 
38 subjects were included and divided as follows: aGHD (n = 18, 6 females and 12 males); healthy controls 
(n = 20, 10 females and 10 males). GHD was diagnosed with dynamic test using Growth Hormone-Releasing 
Hormone (GHRH 50 μg i.v. + arginine 0,5 g/Kg), with a peak GH response < 9 μg/L when BMI was <30 kg/ 
m2 or < 4 μg/L when BMI was >30 kg/m2. The two groups were evaluated for hormonal and metabolic pa-
rameters, CH50 and IgG subtypes. 
IgG1 and IgG2 were significantly higher in controls than in aGHD, while IgG3 and IgG4 showed a trend to 
higher levels in controls, although not significant. Furthermore, CH50 levels were significantly higher in aGHD. 
These data substantiate the hypothesis of a dyscrasia in IgG subclasses production in aGHD. As IgG levels 
decrease, CH50 levels do not.   
1. Introduction 
Adult Growth Hormone Deficiency (aGHD), defined as a reduction in 
GH secretion caused by congenital or acquired disorders affecting the 
hypothalamus or the pituitary gland [1], is a pathological condition 
marked by low-grade chronic inflammation [2]. It shares some features 
with metabolic syndrome, including insulin resistance, altered lipidic 
metabolism, systemic inflammation [3–5] and oxidative stress (OS), 
even if a different pattern of antioxidant response has been shown [6,7]. 
The results of these phenomena are cardiovascular impairment and the 
subsequent complications [8]. Chronic low-grade inflammation (LGI) 
syndromes can be defined as systemic and chronic pathological 
conditions characterized by a slight increase in inflammatory markers. 
Chronic LGI exhibits increased circulating cytokine levels and macro-
phage infiltration in peripheral tissues, which do not cause, anyway, 
damage or loss of function to the involved tissues [9,10]. Different 
chronic inflammatory disorders and autoimmune diseases are accom-
panied by elevated polyclonal free light chains of immunoglobulins 
(FLCs) levels in different body fluids and the increased FLCs concen-
trations correlate with relapses of disease and enhanced activity of the 
immune system [11,12]; an augmented level of both FLCs types (kappa 
and lambda) has recently been described in aGHD [13]. Finally, it is 
known that GH, directly or via Insulin-like growth-factor-1 (IGF-1) ac-
tivity, influences many aspects of immune response; both humoral and 
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cellular branches are modulated [14–18]. GHD has been described as a 
disorder characterized by altered IgG production, even though no clin-
ical consequence of immunodeficiency is evident [19]. However, no 
data on IgG subclasses and complement function are available. 
The complement cascade comprises over 20 serum proteins that form 
part of the innate immune system. Complement acts in a number of ways 
to clear invading organisms, with a major function of lysis of bacteria 
through formation of the membrane attack complex. Complement total 
activity (CH50) is a screening assay for the activation of the classical 
complement pathway, the immunoglobulins mediated-one. It is sensi-
tive to the reduction, absence and/or inactivity of any component of the 
pathway. The CH50 tests the functional capability of serum complement 
components of the classical pathway to lyse sheep red blood cells pre- 
coated with rabbit anti-sheep red blood cell antibody (hemolysin). 
CH50 blood test is often ordered to evaluate complement component 
deficiency and evaluate complement activity in cases of immune com-
plex diseases, such as glomerulonephritis and autoimmune diseases [20, 
21]. 
The subclasses of IgG either may be useful to better understand a 
scenario of altered immune response [22]. The distribution of the IgG 
subclasses depends on the type of antigen and duration of antigen 
exposure, a concept known as “subclass restriction”. Thus, elevations of 
a given IgG subclass could reflect the nature of the underlying driving 
antigen. However, it should be noted that serum levels of IgG subclasses 
do not necessarily correlate with the amount of antibody deposition in 
the tissues, meaning that it is not possible to assume that the elevated 
IgG subclass seen in the serum is certainly involved in driving the disease 
process. In humans, IgG is the predominant antibody class (7− 15 g/L) 
and the four IgG subclasses, termed IgG1, IgG2, IgG3, and IgG4, func-
tionally distinct because of different heavy chain gene usage, differ in 
their ability to fix complement (IgG3 > IgG1 > IgG2 > IgG4) and bind Fc 
receptors. The antigen driven subclass switching is sequential in the 
order IgG3, IgG1, IgG2 and IgG4 and is under T cell control [23,24]. 
Nevertheless, the four IgG subclasses are named in descending order of 
frequency: IgG1 is the most prevalent subclass, making up 60–70 % of 
the total IgG, followed by IgG2 (20–30 %), IgG3 (5–8 %) and lastly IgG4 
that is the least frequent IgG subclass, comprising only up to the 5% of 
total IgG [22,25]. 
To the best of our knowledge no data are reported on CH50 and IgG 
subclasses beheaviour in aGHD. Therefore, we performed a case-control 
study in a group of adult GHD patients evaluating CH50 levels and IgG 
subclasses to further explore the pattern of inflammatory markers in this 
condition. 
2. Materials and methods 
2.1. Patients 
Subjects involved in this study were admitted to the University 
Hospital “Policlinico Gemelli” and were enrolled after being given an 
explanation of purposes and nature of the study, conducted in accor-
dance with the Declaration of Helsinki, as revised in 2013. The study 
was approved by the ethical committee of Catholic University of Rome. 
Upon assessment of the importance of the study and that the information 
resources were appropriately expressed, patients gave their informed 
consent. 
We included 38 patients, divided as follows:  
• aGHD (18 patients, 6 females and 12 males). GHD was diagnosed 
with dynamic test using Growth Hormone-Releasing Hormone 
(GHRH) 50 μg i.v. + arginine 0,5 g/Kg (GHRH/ARG), with a peak GH 
response < 9 μg/L when BMI was < 30 kg/m2 or < 4 μg/L when BMI 
was > 30 kg/m2. Etiologies of GHD were: 7 empty sella, 1 pineal cyst, 
3 post-surgical hypopituitarism, 7 negative MRI pictures (idiopathic 
aGHD).  
• healthy controls (20 patients, 10 females and 10 males). 
Exclusion criteria were: age under 18 or over 75; history of cranial 
hypertension or active cranial hypertension, decompensated type 1 or 2 
diabetes mellitus; autoimmune and infectious diseases; corticosteroid 
treatment (except for topic, inhalatory and oral hydrocortisone as 
replacement regimen); other diseases characterized with low insulin- 
like growth factor-1 (IGF-1) such as liver disease, malabsorption and 
malnutrition; renal failure; active malignancies. No patients received 
GH therapy at the moment of the study enrolment. The GHRH/ARG test 
was performed after an adequate replacement therapy of other pituitary- 
dependent axes; in particular, 1 patient was under levothyroxine treat-
ment for secondary hypothyroidism, 3 patients under hydrocortisone 
treatment for secondary hypoadrenalism, 2 male patients under testos-
terone undecanoate for secondary hypogonadism. All therapies were 
monitored by measuring peripheral hormones’ levels as appropriate. 
2.2. Laboratory investigations 
Both in patients and controls, a basal blood sample was collected at 
08:00 a.m. after an overnight fast; it was centrifugated within 2 h and 
plasma aliquots stored at − 80 ◦C until assayed. The following parame-
ters were determined in both groups: glucose, insulin, total and HDL- 
cholesterol, triglycerides, IGF-1. The method used for hormone assays 
was chemo-luminescent immunoassay for insulin (reference range 3–20 
μUI/mL) and IGF-1 (reference range 80− 330 ng/mL). Serum concen-
trations of IGF-1 were measured by using immunochemiluminometric 
assays on a Roche Modular E170 analyzer according to the manufac-
turer’s recommendations. (Roche Diagnostics, Indianapolis, IN, USA) 
using the consensus statement on the standardization and evaluation of 
IGF-1 [26]. The intra- and inter-assay coefficients of variation (CV) for 
all hormones were, respectively, < 5.0 % and < 7.0 %. Plasma con-
centrations of glucose, total cholesterol, HDL-cholesterol and tri-
glycerides were measured by using enzymatic assays and on Olympus 
AU2700 chemistry analyzer (Olympus America Inc., Center Valley, PA, 
USA) according to manufacter’s instruction. The intra-and inter-assay 
CV for total cholesterol and triglycerides were < 1.5 %, and < 2.5 %, 
respectively. The intra-and inter-assay CV for HDL-cholesterol were <
2.5 %, and < 3.0 %, respectively. LDL cholesterol was calculated by 
Friedewald’s equation: LDL = total cholesterol - (HDL + tri-
glycerides/5). HOMA index was calculated according to the formula 
{[fasting insulin (μU/mL)] * [fasting glucose (mmol/L)]}/22.5 [27]. 
In aGHD group an endocrine evaluation including fT3, fT4, thyroid- 
stimulating hormone (TSH), follicle-stimulating hormone (FSH), lutei-
nizing hormone (LH), estradiol (E2), testosterone (T) and cortisol levels 
was performed. The following methods were used for hormone assay: 
ChemoLuminescent Immunoassay for TSH (reference range 0.35–2.80 
μUI/mL), fT3 (reference range 2.4–4.2 ng/ml), fT4 (reference range 
8.5–16.5 pg/ml), FSH (reference range 2.5–11 mU/mL), LH (reference 
range 2.5–10 mU/mL), E2 (reference range <44 ng/mL), DHEAS 
(reference range 800− 3500 ng/mL), T (reference range. 0.20–2.00 ng/ 
ml), Cortisol (reference range 60− 220 ng/mL). 
The Optilite CH50 Reagent is intended for the quantitative in vitro 
determination of CH50 in human serum and EDTA plasma using the 
Binding Site Optilite Turbidimetric assays analyser (The Binding Site 
Birmingham, UK) [28]. The test consists in liposomes encapsulating 
glucose-6-phosphate dehydrogenase (G6PDH) used to mimic an 
invading microorganism. On addition of sample, antibodies in the re-
agent combine with dinitrophenyl groups on the surface of the lipo-
somes. The resultant complex activates complement in the sample, 
which lyses the liposome, releasing G6PDH to react with 
glucose-6-phosphate and NAD in the reagent. The change in absorbance 
can be measured and is proportional to the complement activity in the 
sample. The comparison to a calibration curve gives a value for the 
unknown patient sample [29]. The four IgG subclasses concentrations 
were measured by turbidimetry through the employment of Human IgG 
and IgG subclass liquid reagent kits (The Binding Site Birmingham, UK) 
with Optilite instrument according to the manufacturer’s 
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recommendations. These kits are intended for quantifying human IgG 
and IgG subclasses. Concentrations are automatically calculated by 
reference to a standard curve stored within the instrument. Reference 
range for subclasses: 3.82–9.29 g/L for IgG1; 2.42–7.0 g/L for IgG2; 
0.22–1.76 g/L for IgG3; 0.04–0.86 g/L for IgG4 [30]. Samples were 
tested according to the manufacturer’s instructions and serum dilutions, 
where necessary, were performed according to the manufacturer’s rec-
ommendations. We selected 20 healthy blood donors in the local pop-
ulation and they have fallen within the references interval indicated by 
manufacturers (data not shown) and then the ranges suggested were 
validated as indicated in CLSI EP 28A3C [31]. 
2.3. Statistical analysis 
The statistical analysis was performed using Prism GraphPad 7, San 
Diego, CA, USA. The sample size was empirical for this observational 
study. The D’Agostino and Pearson test, using a p < 0.05, demonstrated 
a non-parametric distribution of all data analyzed. The differences be-
tween CH50 and IgG subclasses in cases and controls were evaluated by 
Mann-Whitney test. The same test was used to compare hormonal and 
metabolic parameters between the two groups. The correlations be-
tween IgG subclasses, CH50 and metabolic and hormonal parameters 
were evaluated through linear correlation analysis. When a correlation 
was found, Spearman test was used to find out its power. All reported P 
values were two-sided and a value of p < 0.05 was considered statisti-
cally significant. There were no missing data. 
3. Results 
3.1. Patients characteristics 
For the 18 partecipants affected by aGHD the mean ± standard de-
viation (SD) age was 53.4 ± 12.1 years, while mean ± SD BMI was 
29.2 ± 5.8 kg/m2. In aGHD group 33 % were females. Fig. 1 shows the 
results of the GH response to maximal stimulation with GHRH + argi-
nine in the tested patients. Mean peak levels were reached at 60 min 
during the test: 4.6 ± 2.9 μg/L. When considering separately obese vs 
normal BMI subjects, we observed mean GH peak of 1.6 ± 1.4 μg/L in 
patients with BMI equal or greater than 30 Kg/m2 and 5.4 ± 2.7 μg/L in 
patients with BMI lower than 30 Kg/m2. 
For the 20 volunterees of the control cohort 53.1 ± 9.9 years was the 
mean ± SD of age, while mean ± SD BMI was 23.97 ± 4.6 kg/m2. 50 % of 
the control group were females. 
3.2. Metabolic and hormonal data 
Table 1 shows mean ± SD levels of metabolic and hormonal param-
eters. As expected IGF-1 was significantly lower in aGHD 
(109.1 ± 38.8 ng/mL) than controls (194.7 ± 90.5 ng/mL). As metabolic 
parameters are concerned, a trend to increased basal insulin levels 
(14.3 ± 11.9 vs 9.8 ± 8.5) and consequently significant differences in 
HOMA-index were observed in aGHD (3.1 ± 2.5) in comparison to 
controls (1.2 ± 0.6). A trend to worse lipidic pattern, although not sig-
nificant, was shown in aGHD cohort 
3.3. Immunological parameters 
Fig. 2 and Fig. 3 show serum IgG levels in cases and controls. IgG1 
and IgG2 were significantly higher in controls than in aGHD, whether 
IgG3 and IgG4 showed a trend, although not significant, to higher levels 
in controls than in aGHD. Furthermore, CH50 levels were significantly 
higher in aGHD (Fig. 4), although remaining within the reference range. 
At univariate analysis, in aGHD patients we found a significant inverse 
correlation between triglycerides and IgG1 (p = 0.03, Spearman corre-
lation coefficient: − 0.50) and IgG2 (p = 0.04, Spearman correlation 
coefficient: − 0.03), while IgG2 also correlated positively with HOMA 
index (p = 0.02, Spearman correlation coefficient: 0.23). No correlation 
between IGF-1 or peak GH levels and immunological parameters was 
detected. 
4. Discussion 
Our data show that aGHD is characterized by a significant lower 
production of IgG1 and IgG2 and a trend toward lower production of 
IgG3 and IgG4 subclasses, consequently a less active complement classic 
pathway. This datum should be inserted in the complex picture of in-
flammatory and/or oxidative alterations in patients affected by aGHD 
[32–34]. Moreover, correlation studies also suggested a relation with 
metabolic parameters in the same subjects. 
GH and IGF-1 are involved in the regulation of the development and 
function of the immune system [35–37]. Indeed, they are produced and 
secreted by several immunocompetent cells and different cells in the 
immune system express their receptors [38]. Their action may be seen 
both on peripheral immune cells and on central organs of immunity, 
such as the bone marrow and the thymus [39]. GH drives chemotactic 
processes, stimulates monocytes phagocytic function, increases 
lymphocyte subpopulations such as CD3+, CD4+, CD8+, and improves 
the effectiveness of T lymphocyte response [40,41]. 
IGF-1 may exert an important role in linking OS and inflammation. A 
complex interplay does exist between IGF-1 and cytokines; IGF-1 stim-
ulates IL-10 production [14,16], while inhibits the production of other 
proinflammatory cytokines [15,18]. On the contrary, lowering IGF-1 
Fig. 1. Average of the results of the GHRH/ARG combined test response in 
aGHD subjects enrolled in the study. Patients with total GHD (n = 18) have a 
peak of less than 9.0 μg/L when BMI was < 30 kg/m2 or < 4 μg/L when BMI 
was > 30 kg/m2. Mean peak levels were reached at 60 min during the test: 
4.6 ± 2.9 μg/L. When considering separately obese vs normal BMI subjects, we 
observed mean GH peak of 1.6 ± 1.4 μg/L in patients with BMI equal or greater 
than 30 Kg/m2 and 5.4 ± 2.7 μg/L in patients with BMI lower than 30 Kg/m2. 
Table 1 
Metabolic and hormonal parameters. Mean ± SD of metabolic and hormonal 
parameters in the two groups. As expected IGF-1 was significantly lower in 
aGHD than controls. A trend to increased basal insulin levels and consequently 
significant HOMA-index differences was observed in aGHD in comparison to 
controls. A trend to worse lipid pattern was shown in aGHD cohort.   
aGHD Controls 
Total cholesterol (mg/dl) 179.5 ± 41.7 185.8 ± 42.1 
HDL cholesterol (mg/dl) 50.6 ± 12.4 59.6 ± 19.5 
LDL cholesterol (mg/dl) 112.8 ± 32.9 109.6 ± 38.1 
Triglycerides (mg/dl) 102.4 ± 41.9 97.1 ± 38.1 
Glucose (mg/dl) 87.2 ± 14.1 86.6 ± 19.7 
Insulin (μUI/mL) 14.3 ± 11.9 9.8 ± 8.5 
HOMA-IR 3.1 ± 2.5* 1.2 ± 0.6 
IGF-1 (ng/mL) 109.1 ± 38.8* 194.7 ± 90.5 
Notes: *p < 0.05 vs controls. 
Abbreviations: aGHD, adult growth hormone deficiency. 
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augments monocyte chemoattractant protein 1 (MCP-1) serum levels. 
MCP-1 in turn induces recruitment of monocytes and macrophages, as 
demonstrated again in type 2 diabetes and chronic hypertension, two 
conditions associated with OS [17]. Finally, IGF-1 favours the replica-
tion and the survival of myeloid and lymphoid progenitors [42]. In GHD 
patients, GH administration improves the function of the immune sys-
tem [43]. As complement analysis is concerned, Cabellero-Villaraso 
et al. did not observe complement variations, evaluated as C3 and C4 
serum levels, in GHD children before and after GH administration [43]. 
Differently from the previous cited study, we have analyzed classical 
complement pathway through CH50, thus finding higher levels in aGHD 
than healthy controls although not exceeding reference range. It seems 
presumable that classical complement pathway, the immunoglobulins 
mediated-one, is not activated in aGHD, probably for the lowering of IgG 
caused by lower GH secretion. 
As previously stated, the lowering of IgG in aGHD is already known 
[19], even though no data on IgG subclasses are reported. Our datum of 
lower levels of IgG subtypes in aGHD is reasonable according to litera-
ture, as a matter of fact the group of Yoshida [44] reported that GH 
enhance immunoglobulin synthesis (IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, 
and IgM, for instance) in B lymphocytes. In particular, the same group 
supported the idea that GH-induced enhancement is not mediated by 
IGF-I as the enhancement is blocked by anti-GH antibody but not by 
anti-IGF-I antibody or anti-IGF-I receptor antibody [45]. Considering 
that GH receptor is predominantly expressed in B cells, they may be 
considered the most important site of action of GH in the immune system 
[46]. Furthermore, our group has recently described an enhanced 
secretion of FLCs in aGHD [13]; in our study aGHD patients presented 
higher k and λ levels than controls and higher k chains levels in com-
parison to subjects affected by metabolic syndrome [13]. Based on the 
previous described data, it is possibile to assume the presence of a 
“dyscrasia” in the production of immunoglobulins in aGHD. Indeed, an 
increase in FLCs productions corresponds to a lower secretion of IgG 
with complete structure. We must emphasise that IgG subclasses in our 
“case” group, even if lower than healthy controls, were still in reference 
Fig. 2. Mean ± SD IgG1 and IgG2 plasmatic levels in cases and controls. IgG1 and IgG2 were significantly higher in controls than in aGHD. * p < 0.05.  
Fig. 3. Mean ± SD IgG3 and IgG4 plasmatic levels in cases and controls. IgG3 and IgG4 showed a trend, although not significant, to higher levels in controls than 
in aGHD. 
Fig. 4. Mean ± SD CH50 in cases and controls. CH50 levels were significantly 
higher in aGHD, although remaining within the reference range. * p < 0.05. 
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range, thus no worse immune response can be described in aGHD, as 
extensively reported in literature [19,38]. In addition, as stated previ-
ously, none of the patients with aGHD reported infectious or autoim-
mune processes at the moment of the evaluation. 
As regard our aGHD cohort, the most frequent diagnoses were the 
idiopathic and primary empty sella (PES). Original suggestion of hypo-
secretion of GH in primary PES was described by Brismar et al. [47,48]. 
The group of Gasperi showed a large proportion of PES patients with a 
reduced GH response to stimulation and low IGF-1 levels [49]. 
Furthermore, De Marinis et al. described isolated GH deficiency in a 
small group of patients, who presented benefits on quality of life after 
replacement therapy [50]. Moreover, it is known that GHD precedes 
other pituitary deficiencies in case of pituitary insult or damage, sug-
gesting a greater sensitivity of somatotroph cells to different harmful 
stimuli [51]. Several aspects of pathophysiology of PES are unknown, as 
neurotransmitter control and autoimmune factors, other than the direct 
compression of the gland parenchyma. The prevalence of idiopathic 
GHD, 38 % in our cohort, is different among literature reports. In the 
observational HYPOCCS database, from 1996 to 2005, an increase from 
13.9–19.3% was reported [52]. About 10 % patients were classified as 
idiopathic in the KIMS observational study [53]. The prevalence was 
also related to regional differences, from 2.6 % in the Netherlands to 65 
% in UK; probably, a better knowledge about possible genetic or auto-
immune aetiology of GHD, may narrow the field of “idiopathic” GHD. 
Nevertheless, there are some main potential restrictions to be 
considered about the present study. First, the number of subjects in the 
groups is slightly small, so the statistical power of the study is limited, 
even if aGHD is considered a rare condition; consequently, our findings 
will need to be confirmed in a larger population. Secondly, the design of 
the study and the power analysis cannot draw a cause-effect relation. 
Finally, more data and longitudinal studies will be needed to strentghten 
the hypotheses here proposed. 
5. Conclusions 
In conclusion, these data substantiate the hypothesis of a dyscrasia in 
IgG production in aGHD. An increase in FLCs production, previously 
reported by our group, could correspond to a lower secretion of IgG with 
complete structure. They should be inserted in the complex scenario of 
inflammation and oxidative stress markers underlying the greater 
morbidity and mortality of GHD, an underestimated disease with a 
physiopathology not still entirely understood. In the era of precision 
medicine, the ability to accurately measure specific predictors of patient 
outcomes may improve the quality of laboratory diagnosis in personal-
ized clinical care. However, these data cannot be conclusive and further 
studies are needed to establish the role of such molecules as biological 
markers and their usefulness in prognostic and personalized treatment 
of such condition. 
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C. Baffoni, M. Cosottini, L. Curtò, F. Trimarchi, G. Lombardi, L. Grasso, E. Ghigo, 
E. Martino, Impairment of GH secretion in adults with primary empty sella, 
J. Endocrinol. Invest. 25 (2002) 329–333, https://doi.org/10.1007/BF03344013. 
[50] L. De Marinis, S. Bonadonna, A. Bianchi, G. Maira, A. Giustina, Primary empty 
sella, J. Clin. Endocrinol. Metab. 90 (2005) 5471–5477, https://doi.org/10.1210/ 
jc.2005-0288. 
[51] S. Melmed, Idiopathic adult growth hormone deficiency GH secretion and action, 
J. Clin. Endocrinol. Metab. 98 (2013) 2187–2197, https://doi.org/10.1210/ 
jc.2012-4012. 
[52] S.M. Webb, C.J. Strasburger, D. Mo, M.L. Hartman, S. Melmed, H. Jung, W.F. Blum, 
A.F. Attanasio, Changing patterns of the adult growth hormone deficiency 
diagnosis documented in a decade-long global surveillance database, J. Clin. 
Endocrinol. Metab. 94 (2009) 392–399, https://doi.org/10.1210/jc.2008-0713. 
[53] R. Abs, B.Å. Bengtsson, E. Hernberg-Ståhl, J.P. Monson, J.P. Tauber, P. Wilton, 
C. Wüster, GH replacement in 1034 growth hormone deficient hypopituitary 
adults: demographic and clinical characteristics, dosing and safety, Clin. 
Endocrinol. (Oxf). 50 (1999) 703–713, https://doi.org/10.1046/j.1365- 
2265.1999.00695.x. 
E. Vergani et al.                                                                                                                                                                                                                                 
